FIGURE

Fig. 6

ID

ZDB-FIG-240515-39

Publication

Hao et al., 2024 - Somatic PDGFRB activating variants promote smooth muscle cell phenotype modulation in intracranial fusiform aneurysm

Other Figures

All Figure Page

Back to All Figure Page

Fig. 6

Ruxolitinib can reverse the phenotype caused by the PDGFRβ.^Y562D in zebrafish. A The timeline of human WT/Y562D PDGFRβ mRNA treatment and medication administration: Embryos are injected human WT/Y562D PDGFRβ mRNA at one-cell stage and treated with Ruxolitinib at 24 h post-fertilization (24 hpf) and preserve at 3 days post-fertilization (3 dpf). B and C Immunostaining of kdrl:eGFP + cells and erythrocytes(αe1) in the head of a 3 dpf embryos treated or not with Ruxolitinib. Statistical significance is determined using Student's t-test and Benjamini–Hochberg correction. ns, no significant; *padj < 0.05, **padj < 0.01, ***padj < 0.001, ****padj < 0.0001

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ J. Biomed. Sci.